Latest News & Updates
Breaking News
8 minutes ago
Simantini Singh Deo
Other trending news you may like to read
Ajax Therapeutics Secures Orphan Drug Designation From FDA For AJ1-11095 Advancing Therapy Options In Myelofibrosis
FDA grants Orphan Drug Designation to Ajax Therapeutics’ AJ1-11095. A first-in-class type II JAK2 inhibitor advancing treatment options for myelofibrosis patients.
Simantini Singh Deo
Pfizer’s TUKYSA Delivers Significant PFS Benefit In Phase 3 HER2CLIMB-05 Trial; Tucatinib Combo Shows Extended First-Line Outcomes For HER2+ MBC
Pfizer’s HER2CLIMB-05 trial shows TUKYSA in first-line maintenance cut disease progression risk by 35.9%, extending PFS for HER2+ metastatic breast cancer.
Vaibhavi M.
Valneva’s IXCHIQ® Shows Strong One-Year Immunity And Safety In Children, Clearing Path Toward Phase 3 Trials; Delivering Robust 12-Month Protection Against Chikunguny
Valneva reports strong Phase 2 pediatric results for its single-shot chikungunya vaccine, supporting full-dose use as it advances toward Phase 3 development.
Vaibhavi M.
Kane Biotech Gains Health Canada Approval For revyve® Antimicrobial Wound Gel Spray,Strengthening Kane Biotech’s Growing Wound Care Portfolio
Kane Biotech secures Health Canada approval for its revyve® Antimicrobial Wound Gel Spray, expanding advanced wound care options for complex and hard-to-heal wounds.
Vaibhavi M.
